Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial

Circulation. Heart failure - United States
doi 10.1161/circheartfailure.118.004962
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Prognosis in Heart Failure With Preserved Ejection Fraction

sudan heart journal
2017English

Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction: A Randomized Clinical Trial (Empire HF)

Trials
MedicinePharmacology
2019English

Prognosis of Heart Failure With Stable Mid-Range Ejection Fraction in Comparison to Heart Failure With Stable Reduced Ejection Fraction and Heart Failure With Stable Preserved Ejection Fraction

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2019English

Microvascular Rarefaction and Heart Failure With Preserved Ejection Fraction

Frontiers in Cardiovascular Medicine
Cardiovascular MedicineCardiology
2019English

Spironolactone for Heart Failure With Preserved Ejection Fraction

New England Journal of Medicine
Medicine
2014English

Heart Failure in Patients With Preserved and Deteriorated Left Ventricular Ejection Fraction

Heart
Cardiovascular MedicineCardiology
2005English

Effect of Ivabradine in Patients With Heart Failure With Preserved Ejection Fraction: The EDIFY Randomized Placebo-Controlled Trial

European Journal of Heart Failure
Cardiovascular MedicineCardiology
2017English

Association Between Hyperuricemia and Mortality in Heart Failure Patients With Preserved Ejection Fraction

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2015English

Echocardiographic Patterns of Cardiac Amyloidosis in Patients With Heart Failure With Preserved Ejection Fraction

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy